Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (41-50 of 214) with videos related to

Pageof 22
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 23, 2026
Seladelpar improves cholestasis and pruritus in obeticholic acid and fibrate-experienced patients with PBCStuart C Gordon, Sarah Proehl, Daniel Pratt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2013
Cost-effectiveness of screening for chronic hepatitis C infection in the United StatesMark H Eckman, Andrew H Talal, Stuart C Gordon, et al.
Medicine|October 15, 2016
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of careZobair M Younossi, Haesuk Park, Douglas Dieterich, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2016
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?Zobair M Younossi, Haesuk Park, Douglas Dieterich, et al.
Clinical Reviews in Allergy & Immunology|May 10, 2005
Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosisYasunori Ichiki, Carlo Selmi, Shinji Shimoda, et al.
Hepatology Communications|July 7, 2020
Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 ScoreStuart C Gordon, Nandita Kachru, Emily Parker, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 25, 2014
Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3Kristin G Monaghan, Humberto C Gonzalez, Albert M Levin, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' replyRohit Loomba, Robert Wong, Jeremy Fraysse, et al.
Alimentary Pharmacology & Therapeutics|May 7, 2020
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare dataRohit Loomba, Robert Wong, Jeremy Fraysse, et al.
Case Reports in Hepatology|September 5, 2020
A Case of Hemophagocytic Lymphohistiocytosis Secondary to Disseminated HistoplasmosisIvan Columbus-Morales, Lucas Maahs, Sanam Husain, et al.
Pageof 22

Showing results (41-50 of 214) with videos related to

Sort By:
Pageof 22
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 23, 2026
Seladelpar improves cholestasis and pruritus in obeticholic acid and fibrate-experienced patients with PBCStuart C Gordon, Sarah Proehl, Daniel Pratt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2013
Cost-effectiveness of screening for chronic hepatitis C infection in the United StatesMark H Eckman, Andrew H Talal, Stuart C Gordon, et al.
Medicine|October 15, 2016
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of careZobair M Younossi, Haesuk Park, Douglas Dieterich, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 3, 2016
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?Zobair M Younossi, Haesuk Park, Douglas Dieterich, et al.
Clinical Reviews in Allergy & Immunology|May 10, 2005
Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosisYasunori Ichiki, Carlo Selmi, Shinji Shimoda, et al.
Hepatology Communications|July 7, 2020
Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 ScoreStuart C Gordon, Nandita Kachru, Emily Parker, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 25, 2014
Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3Kristin G Monaghan, Humberto C Gonzalez, Albert M Levin, et al.
Alimentary Pharmacology & Therapeutics|May 20, 2020
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' replyRohit Loomba, Robert Wong, Jeremy Fraysse, et al.
Alimentary Pharmacology & Therapeutics|May 7, 2020
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare dataRohit Loomba, Robert Wong, Jeremy Fraysse, et al.
Case Reports in Hepatology|September 5, 2020
A Case of Hemophagocytic Lymphohistiocytosis Secondary to Disseminated HistoplasmosisIvan Columbus-Morales, Lucas Maahs, Sanam Husain, et al.
Pageof 22